WO2023228093 - CD19 CAR NK CELLS FOR USE IN METHODS OF TREATING CANCER
National phase entry:
Publication Number
WO/2023/228093
Publication Date
30.11.2023
International Application No.
PCT/IB2023/055311
International Filing Date
23.05.2023
Title **
[English]
CD19 CAR NK CELLS FOR USE IN METHODS OF TREATING CANCER
[French]
CELLULES NK CAR CD19 DESTINÉES À ÊTRE UTILISÉES DANS DES MÉTHODES DE TRAITEMENT DU CANCER
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
SELLNER, Leopold
KASAR, Siddha, Narayan
CARSILLO, Mary, E.
CURLEY, Michael, David
Priority Data
63/344,962
23.05.2022
US
63/348,220
02.06.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2503 | |
| EPO | Filing, Examination, Granting | 14177 | |
| Japan | Filing, Examination, Granting | 2511 | |
| South Korea | Filing, Examination, Granting | 2762 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
27,893
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides, among other things methods and compositions for the treatment of cancer comprising administering CD19 CAR cord blood derived natural killer (CB-NK) cells to a patient in need thereof.[French]
La présente divulgation concerne, entre autres, des méthodes et des compositions pour le traitement du cancer comprenant l'administration de cellules tueuses naturelles dérivées du sang de cordon CAR CD19 (CB-NK) à un patient en ayant besoin.